Plot No. 11 & 84, TSIIC Phase: IV
Pashamylaram (V) Patancheru (M) Sangareddy District
Hyderabad 502307
India
91 84 5569 9999
https://www.glandpharma.com
Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 4.209
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Srinivas Sadu | MD, CEO & Executive Chairman | 123,58M | N/A | 1969 |
Mr. Ravi Shekhar Mitra | Chief Financial Officer | 15,15M | N/A | 1977 |
Mr. Sampath Kumar Pallerlamudi | Company Secretary & Vice-President of Compliance & CSR | 5,11M | N/A | 1981 |
Mr. Satnam Singh Loomba | Chief Operating Officer | N/A | N/A | 1968 |
Mr. Ankit Gupta | Head of Investments, Strategy & Investor Relations | N/A | N/A | N/A |
Mr. Surinder Koul | Head of Domestic Marketing | N/A | N/A | N/A |
Ms. Shilpi Sahay | Deputy General Manager of Human Resources | N/A | N/A | 1981 |
Dr. C. S. Venkatesan | Senior Vice President of R&D | N/A | N/A | 1971 |
Dr. Surapanini Sridevi | Senior Vice President of R&D | N/A | N/A | 1968 |
Mr. K Raghuramachandra Rao | Head of Quality | N/A | N/A | N/A |
Gland Pharma Limited engages in manufacturing and sale of injectable formulation in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical API products including synthesis of complex drug molecules, such as LMWH, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro intestinal, gynecological, hormones, neuro/Cns, ophthal/ontological, and other areas, as well as pain and analgesics, respirator, and vitamins, minerals and nutrients; and offers contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Gland Pharma Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.